Mechanism of Action/Pathway Profiles

Mechanism of Action Magnifier – 2016 Desk Reference

Welcome to the inaugural edition of our annual Mechanism of Action Magnifier™! The Magnifier series is an exclusive supplement brought to you by the publishers of Personalized Medicine in Oncology (PMO) to delve into the biochemical interaction through which an oncology drug produces its pharmacological effect.

View Supplement

Mechanism of Pathway: Phosphatidylserine, an Immune-Modulating Checkpoint, Ushers in the Next Wave of Immuno-Oncology Targets
  • Phosphatidylserine (PS) is an immune checkpoint distinct from PD-1/PD-L1, CTLA-4, and other antagonists or agonists of T-cell activation
  • Tumors compromise the body’s normal immunosuppressive process of clearance/disposal of dying cells through PS-signaling mechanisms to evade immune detection
  • PS exposure in the tumor microenvironment is immunosuppressive and increases in response to chemotherapy and radiation therapy
  • Bavituximab is an investigational monoclonal antibody that targets PS and is believed to override PS-mediated immunosuppressive signaling in tumors prevalent in the tumor microenvironment, as well as to provide an immune-activating signal through Fc-γ receptor signaling

View Supplement

Case Presentation: Targeted Therapy in Metastatic Melanoma

The management of melanoma has entered an era of biomarker-driven targeted therapy and immunotherapy. The following case, presented by Sanjiv S. Agarwala, MD, at PMO Live 2015, illustrates the 2015 approach to the management of metastatic melanoma. Case: Metastatic Melanoma A 56-year-old female with a history of T2N2b melanoma and [ Read More ]

Mechanism of Action/Pathway Profiles, PMO Live - Global Biomarkers Consortium

Molecular Pathways in Cancer Are Increasingly Being Exploited

Molecular pathways in cancer can be exploited for therapy, and sensitizing genetic aberrations are the ideal targets, said Alex Adjei, MD, PhD, at PMO Live 2015. Cancer cells have to evade a number of stresses to grow. They are complex and live in a toxic environment, but somehow they manage [ Read More ]

Mechanism of Action/Pathway Profiles, PMO Live - Global Biomarkers Consortium

Two Cases of Triple-Hit Lymphoma: A Call for Imperative MYC, BCL2, and BCL6 Testing by FISH in Aggressive Lymphomas

Remission in aggressive B-cell lymphomas is increasingly linked to complex karyotypes and gene rearrangements that often portend aggressive behavior and resistance to standard therapy. An understanding of lymphoma cytogenetics has lagged behind that of leukemia, in which pretreatment karyotype constitutes an independent prognostic determinant for attainment of complete remission. In [ Read More ]

Joshua Brody, MD
Hematological Malignancies, Mechanism of Action/Pathway Profiles

Confirming Diagnoses and Identifying Biomarkers Linked to Targeted Treatments with the bioT3 Approach

The current generation of oncologists has witnessed great advances in our understanding of tumor biology and biomarkers linked to treatments. Those advances started with research, but disseminating this information can be difficult given the myriad of obstacles in adoption to practice. The science behind these advances is fascinating and excites [ Read More ]

Ralph V. Boccia, MD, FACP
Interview with the Innovators, Mechanism of Action/Pathway Profiles

The Ultimate Target of Personalized Oncology Treatment: Improving the Lives of Our Patients

Dear Colleague, The landscape of cancer care has evolved tremendously over the past decade in every aspect: research targets, available treatments, management strategies, even the makeup of the oncology multidisciplinary team. The publishers of Personalized Medicine in Oncology (PMO) recognize the importance of providing information for the entire oncology team [ Read More ]

Letter to Our Readers, Mechanism of Action/Pathway Profiles

Mechanism of Action: Key Advances in Hematology Oncology

As evidenced by the 2013 annual meetings of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the European Hematology Association (EHA), the pace at which scientific knowledge is influencing cancer drug development is astounding. Breakthroughs in our collective understanding of the underlying biology of solid and liquid tumors have revolutionized cancer treatment compared with as few as 5 years ago.

View Supplement